South Korea-based DAAN Biotherapeutics has entered a licensing agreement with GC Cell, granting the latter exclusive rights ...

Addressing the accessibility and high costs of chimeric antibody receptor (CAR) T-cell and bispecific therapies is crucial for maximizing their impact in multiple myeloma (MM). Patients once ...

Biotechnology company Eutilex is developing a portfolio of immuno-oncology T cell, chimeric antigen receptor T cell and antibody therapeutics that are now ready for partnering. Founded in 2015 and ...